A Randomized Trial Compared the Efficacy and Safety of Combined Use of Indocyanine Green Fluorescence and Methylene Blue Dye Versus Methylene Blue Dye alone for Sentinel Lymph Node Biopsy in Breast Cancer Patients
Peking University People's Hospital Breast Cancer Center
100 participants
Jan 5, 2011
Interventional
Conditions
Summary
Methylene blue is widely used in developing country for SLNB.The ICG is an innovative fluorescent tracer that could be visualized by near-infrared camera.This trial is designed to compare the efficacy and Safety of Combined Use of ICG Fluorescence and Methylene Blue Dye versus dye alone for SLNB in Breast Cancer Patients.
Eligibility
Inclusion Criteria3
- Histologically diagnosed as invasive breast cancer (T1-T3)
- Clinical negative axillary lymph node
- No distant metastasis
Exclusion Criteria4
- Histologically identified positive lymph node
- Palpable positive lymph node
- A positive history of anaphylaxis or iodine allergy
- A history of axillary surgery
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The patients are randomly assigned to one of two groups, receiving combined use of ICG and methylene blue(Combination Group) or methylene blue alone as the lymphatic mapping tracer.Methylene blue will be injected periareolarly or peritumorally 8 minutes before the standard biopsy insicion.In the combination group,ICG would be injected 3 minutes before the surgery.In the combination group, sentinel lymph nodes are identified by ICG fluorescence using a near-infrared camera and blue stained lymph nodes found during this precedure will also be resected, while in blue dye alone group, sentinel lymph nodes are identified as blue nodes along the blue lymphatic vessel.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000109808